SEC Filing Summary: BioSig Technologies, Inc. (BSGM)
Business Context and Reporting Period
This Form 8-K Current Report, dated July 2, 2021, details a material definitive agreement entered into by BioSig Technologies, Inc. (the "Company"). The filing reports on an underwritten public offering of common stock executed on July 2, 2021, with an expected closing date of July 7, 2021.
Key Financial Metrics and Transaction Details
- Offering Size: 2,500,000 shares of Common Stock.
- Public Offering Price: $4.00 per share.
- Underwriter Purchase Price: $3.68 per share.
- Expected Net Proceeds: $9,200,000 (after underwriting discount, before offering expenses).
- Over-Allotment Option: Underwriter granted an option to purchase up to 375,000 additional shares (15% of the offering) at $3.68 per share for 30 days.
- Underwriter Warrants: 125,000 warrants (5% of shares sold) issued to the underwriter, exercisable at $4.80 per share (120% of public price) for five years on a cashless basis.
- Reimbursable Expenses: Company to reimburse underwriter for out-of-pocket expenses up to $100,000.
Material Changes and Unusual Items
The filing does not provide comparative financial data (revenue, profit, cash flow, or margins) as it is a current report regarding a specific capital event rather than a periodic financial statement. The primary material change is the dilution of existing shareholders due to the issuance of new shares and the potential issuance of option shares and warrants. The filing notes that the offering is subject to customary closing conditions.
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance on revenue or earnings. The primary risk disclosed relates to the dilution of equity and the terms of the underwriting agreement, including the over-allotment option and warrant issuance. The Company has agreed to indemnify the underwriter for certain liabilities arising under the Securities Act of 1933.
Investor Verification Checklist
- Verify the final closing date of the offering (expected July 7, 2021) and confirm the actual net proceeds received.
- Confirm whether the underwriter exercises the 375,000 share over-allotment option within the 30-day window.
- Review the final prospectus supplement for any changes to the use of proceeds or offering expenses.
- Monitor the Company's cash position post-closing to assess liquidity improvements.
- Check subsequent filings for the impact of the new share issuance on earnings per share (EPS) and total share count.